The SELECT Trial: How Semaglutide Became a Cardiometabolic Therapy

For most of its public life, semaglutide has been discussed as a weight-loss drug. The SELECT trial is the study that complicated — and arguably rewrote — that framing. Published in the New England Journal of Medicine in December 2023, SELECT tested a simple but consequential question: in people who carry cardiovascular disease and excess weight but not diabetes, does semaglutide reduce actual cardiovascular events? The answer it produced reshaped how regulators, clinicians, and researchers categorize the entire GLP-1 class.

This is a research log entry, not medical advice. The point here is to look at what SELECT actually measured and what its results do — and don't — support.

What SELECT was designed to test

SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) was a large, randomized, double-blind, placebo-controlled cardiovascular outcomes trial. It enrolled 17,604 participants — 8,803 assigned to semaglutide and 8,801 to placebo. To qualify, participants had to be adults with established cardiovascular disease (prior heart attack, prior stroke, or symptomatic peripheral artery disease), a BMI of 27 or higher, and no history of type 2 diabetes. The cohort skewed older and male: mean age was roughly 62, about 72% were men, and the average BMI was around 33.

Participants received either subcutaneous semaglutide titrated to 2.4 mg once weekly — the same dose marketed as Wegovy for weight management — or matching placebo, on top of standard cardiovascular care. Mean follow-up ran nearly 40 months, long enough to accumulate meaningful event data rather than just short-term surrogate markers like weight or blood pressure.

The design detail that matters most: the primary endpoint was a hard clinical composite, not a weight number. That is what separates a cardiovascular outcomes trial from a weight-loss study.

The headline result: a 20% reduction in MACE

The primary endpoint was major adverse cardiovascular events (MACE) — a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

In the semaglutide group, 6.5% of participants experienced a primary-endpoint event, compared with 8.0% in the placebo group. That corresponds to a hazard ratio of 0.80 (95% CI, 0.72–0.90) — a 20% relative risk reduction, and the result was statistically significant.

The secondary and supportive findings fill in the picture, with the usual caveats about hierarchical testing:

One of the more interesting interpretive questions is why the benefit appeared. The event curves began separating relatively early, and the magnitude of benefit was larger than weight loss alone would easily explain. That has fueled ongoing discussion about direct effects on inflammation, vascular biology, and blood pressure — mechanisms beyond the scale. SELECT does not resolve that debate; it documents the outcome.

Why the regulatory follow-through mattered

A positive trial is one thing; a label change is another. In March 2024, the FDA expanded Wegovy's (semaglutide 2.4 mg) approved indication to include reducing the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with established cardiovascular disease who have obesity or overweight. It was described as the first weight-management medication also cleared to help prevent major cardiovascular events in this population.

That distinction is worth sitting with. An off-label observation that a weight drug "might be good for the heart" is not the same as a regulator reviewing outcomes data and formally recognizing a cardiovascular indication. You can track how such approvals and indications are categorized on our FDA status reference. The label expansion took SELECT out of the realm of promising secondary findings and made cardiovascular risk reduction a stated, evidence-backed use.

From "weight drug" to cardiometabolic therapy

The conceptual shift SELECT helped drive is the reason it gets cited so often. GLP-1 receptor agonists first entered practice for type 2 diabetes, then broke through publicly for weight loss. SELECT added a third pillar: event-level cardiovascular protection in people without diabetes. That combination — glucose, weight, and cardiovascular outcomes — is what the term "cardiometabolic" is meant to capture.

It is worth being precise about the boundaries. SELECT studied a specific population: adults with established cardiovascular disease and overweight/obesity, without diabetes. It does not demonstrate cardiovascular benefit in people at low baseline risk, and it is not a primary-prevention trial. Extrapolating the 20% figure to healthy individuals looking to lose weight goes well beyond what the data support. The trial's strength is precisely its specificity.

The bottom line for a research log

SELECT is a landmark because it moved semaglutide's evidence base from surrogate endpoints to hard outcomes in a group where nobody had proven the benefit before. A 20% MACE reduction over ~40 months, in ~17,600 people without diabetes, followed by a formal FDA indication, is the kind of result that redefines a drug class. It reframed GLP-1 therapy as cardiometabolic medicine rather than cosmetic weight loss.

As always, primary sources are the place to verify any of this — the NEJM report (Lincoff et al., 2023) and the current FDA label are the authoritative references, and both can update over time.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.